Drugs / MG1111
MG1111
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02367638 | Mar → Jul 2015 | chickenpox | Green Cross Corporation | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05422508 | Jul 2022 → Jun 2025 overdue | chickenpox | Green Cross Corporation | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03375502 | Nov 2016 → Jan 2019 | — | Green Cross Corporation | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07054099 | Mar 2026 → Aug 2027 expected | chickenpox | GC Biopharma Corp | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05664152 | Feb → Apr 2023 | varicella zoster infection | GC Biopharma Corp | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MG1111 | “A Study of MG1111 in Healthy Children” NCT03375502 ↗ |
| Known as | BARICELA | “Biological: MG1111 (BARICELA)” NCT05422508 ↗ |
| Known as | BARYCELA inj. | “Participants will be administered subcutaneously with a single dose(0.5 mL dose) of the BARYCELA inj.(MG1111)” NCT05664152 ↗1“MG1111 (Barycela inj.)” NCT07054099 ↗ |
| Modality | Vaccine | “Live Attenuated Varicella Vaccine for Injection” NCT05664152 ↗ |
| Route | Subcutaneous | “0.5ml, single dose, subcutaneous injection” NCT05422508 ↗ |